Novavax Global Commercial Operations and COVID-19 Vaccine Update

Robust neutralization responses in adolescents after boosting All participants, 12-17 y/o (N=45) Pseudovirus Neutralization GMT (ID50) with 95% CI 9,131 10,000 5,370 1,000 100 10 Prototype Delta 318 173 12,669 7,426 BA.1 BA.4/5 Prototype After primary series novavax Validated assay conducted by Monogram Includes All Participant Data *Correlates of Protection inferred from Fong, Y., et al., 2023. DOI: 10.1038/s41467-022-35768-3 Delta PREVENT-19 PRE-fusion Protein Subunit Vaccine Efficacy Novavax Trial | COVID-19 4,538 4,276 93% VE* BA.1 After homologous boost BA.4/5 82% VE* 76% VE* © 2023 NOVAVAX. All rights reserved. 42

View entire presentation